APGE Apogee Therapeutics
- 47.250
- -0.990-2.05%
- 47.250
- 0.0000.00%
Apogee Therapeutics News
BofA Securities Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $80
Apogee Therapeutics, Inc. (APGE) Receives a Buy From TD Cowen
Buy Rating for Apogee Therapeutics: Promising Prospects for Dupixent and APG808 in COPD Market
Buy Rating on Apogee Therapeutics: Promising Drug Developments and Strong Financials
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics Analyst Ratings
Apogee Therapeutics (APGE.US) was first covered by B of A Securities, giving it a buy rating, with a target price of $80.00.
Buy Rating Affirmed for Apogee Therapeutics as APG777 Shows Promise and Pipeline Progresses
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics, Inc. (APGE), SAGE Therapeutics (SAGE)
Jefferies Maintains Buy on Apogee Therapeutics, Raises Price Target to $75
Buy Rating Endorsed for Apogee Therapeutics Amid Promising APG777 Phase 1 Results
Apogee Therapeutics Analyst Ratings
Stifel Nicolaus Sticks to Its Buy Rating for Apogee Therapeutics, Inc. (APGE)
Stifel Nicolaus Keeps Their Buy Rating on Apogee Therapeutics, Inc. (APGE)
Guggenheim Maintains Buy on Apogee Therapeutics, Raises Price Target to $44
Apogee Therapeutics Analyst Ratings
BTIG Sticks to Its Buy Rating for Apogee Therapeutics, Inc. (APGE)
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics, Inc. (APGE), Apollo Medical Holdings (AMEH) and Alcon (ALC)
BTIG Initiates Coverage On Apogee Therapeutics With Buy Rating, Announces Price Target of $43
Apogee Therapeutics Analyst Ratings
Analysis
Price Target
No Data
